Physician profile
Carma E Ball
NPI 1356733638
$4,927.76
in general payments reported to CMS, 2019-2025
49 companies · $1,990 in 2025
The $1,990 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $276 · 2022: $689 · 2023: $605 · 2024: $1,368 · 2025: $1,990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,962.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,133.37 | 2021-2025 | |
| Ucb, INC. | $369.96 | 2021-2025 | Briviact, Nayzilam, Rystiggo |
| Lundbeck LLC | $290.28 | 2022-2025 | Vyepti, Rexulti |
| Axsome Therapeutics, INC. | $249.52 | 2023-2025 | Symbravo, Sunosi |
| Eisai INC. | $232.51 | 2023-2025 | |
| Lilly USA, LLC | $228.42 | 2022-2025 | Kisunla, Amyvid, Emgality |
| Pfizer INC. | $212.56 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $174.90 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Jazz Pharmaceuticals INC. | $144.87 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $133.08 | 2023-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $109.44 | 2025 | Ponvory |
| Sk Life Science, INC. | $106.42 | 2022-2024 | |
| Acadia Pharmaceuticals INC | $98.81 | 2022-2025 | Nuplazid |
| Amgen INC. | $95.35 | 2021-2023 | Aimovig |
| Ani Pharmaceuticals, INC. | $89.61 | 2024-2025 | Purified Cortrophin Gel |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carma Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.